MedTrace Logo

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

NCT01045863 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2010-08-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and tolerability after a single administration of PF-03382792 in healthy volunteers.; and to evaluate plasma drug levels and biological activity.

Conditions

  • Healthy

Interventions

DRUG

PF-03382792 Cohort 1

First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.

DRUG

PF-03382792 Cohort 2

Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.

DRUG

PF-03382792

Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.

DRUG

Food Effect cohort

Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.

DRUG

CSF cohort

Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01045863 on ClinicalTrials.gov